AI and Computer Vision-Assisted Telerehabilitation in Fibromyalgia: The FibroIA 2.0 Trial

Fibromyalgia (FM) is a primary chronic pain condition with an estimated prevalence of 3.3% in Chile. It is characterized by widespread musculoskeletal pain, fatigue, and impaired physical function. Although exercise therapy is considered the first-line intervention, barriers to access and poor adherence limit its effectiveness within the public healthcare system. This study evaluates the effectiveness of an Artificial Intelligence (AI)- and Computer Vision (CV)-assisted telerehabilitation platform called Rehbody. The aim is to determine whether real-time technology-driven feedback can overcome the limitations of traditional face-to-face rehabilitation models by improving disease impact and functional capacity in Chilean patients with fibromyalgia.

Inclusion Criteria: * Adults aged 18 years or older, of any sex/gender, with a documented medical diagnosis of fibromyalgia established in primary or secondary healthcare settings according to the American College of Rheumatology (ACR) criteria (Häuser \& Fitzcharles, 2018). * Individuals able to understand and complete the self-report questionnaires used in the study. * Individuals with access to a compatible electronic device (smartphone, tablet, or computer) and an internet connection required for participation in the telerehabilitation intervention. * Individuals with basic digital literacy skills, defined as the ability to use electronic devices and interact with commonly used applications. * Individuals who provide written informed consent to participate in the study. Exclusion Criteria: * Current participation in another structured therapeutic exercise program, whether supervised or unsupervised. * Moderate to severe functional dependence in activities of daily living, defined as a score \250 mg/dL or \